CN102596906A - 吲哚衍生物作为nurr-1激活剂用作治疗帕金森病的药剂的用途 - Google Patents

吲哚衍生物作为nurr-1激活剂用作治疗帕金森病的药剂的用途 Download PDF

Info

Publication number
CN102596906A
CN102596906A CN2010800509223A CN201080050922A CN102596906A CN 102596906 A CN102596906 A CN 102596906A CN 2010800509223 A CN2010800509223 A CN 2010800509223A CN 201080050922 A CN201080050922 A CN 201080050922A CN 102596906 A CN102596906 A CN 102596906A
Authority
CN
China
Prior art keywords
methyl
group
indol
sulfonyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800509223A
Other languages
English (en)
Chinese (zh)
Inventor
热罗姆·阿莫德吕托
贝纳塞·布比亚
玛丽亚·约翰娜·彼得罗内拉·范·东恩
法布里斯·吉列尔
奥利维尔·普帕迪内-奥利维亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratories Fournier SAS
Original Assignee
Laboratories Fournier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratories Fournier SAS filed Critical Laboratories Fournier SAS
Publication of CN102596906A publication Critical patent/CN102596906A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
CN2010800509223A 2009-09-11 2010-09-10 吲哚衍生物作为nurr-1激活剂用作治疗帕金森病的药剂的用途 Pending CN102596906A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0956259A FR2950053B1 (fr) 2009-09-11 2009-09-11 Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR0956259 2009-09-11
FR1050107A FR2950058B1 (fr) 2009-09-11 2010-01-08 Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR1050107 2010-01-08
PCT/FR2010/051884 WO2011030068A1 (fr) 2009-09-11 2010-09-10 Utilisation de derives d'indole comme activateurs de nurr-1, pour leur application en tant que medicament pour le traitement de la maladie de parkinson

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310415421.6A Division CN103554006A (zh) 2009-09-11 2010-09-10 吲哚衍生物作为nurr-1激活剂用作治疗帕金森病的药剂的用途

Publications (1)

Publication Number Publication Date
CN102596906A true CN102596906A (zh) 2012-07-18

Family

ID=42061922

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800509223A Pending CN102596906A (zh) 2009-09-11 2010-09-10 吲哚衍生物作为nurr-1激活剂用作治疗帕金森病的药剂的用途
CN201310415421.6A Pending CN103554006A (zh) 2009-09-11 2010-09-10 吲哚衍生物作为nurr-1激活剂用作治疗帕金森病的药剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310415421.6A Pending CN103554006A (zh) 2009-09-11 2010-09-10 吲哚衍生物作为nurr-1激活剂用作治疗帕金森病的药剂的用途

Country Status (27)

Country Link
US (1) US20120232070A1 (enExample)
EP (1) EP2475642A1 (enExample)
JP (1) JP2013504548A (enExample)
KR (1) KR20120065345A (enExample)
CN (2) CN102596906A (enExample)
AR (1) AR078358A1 (enExample)
AU (1) AU2010294018A1 (enExample)
BR (1) BR112012005480A2 (enExample)
CA (1) CA2772697A1 (enExample)
CL (1) CL2012000632A1 (enExample)
CO (1) CO6511224A2 (enExample)
CR (1) CR20120131A (enExample)
DO (1) DOP2012000061A (enExample)
EC (1) ECSP12011718A (enExample)
FR (2) FR2950053B1 (enExample)
IL (1) IL218526A0 (enExample)
IN (1) IN2012DN02005A (enExample)
MX (1) MX2012003027A (enExample)
NZ (1) NZ598576A (enExample)
PE (1) PE20121346A1 (enExample)
PH (1) PH12012500390A1 (enExample)
RU (1) RU2012110883A (enExample)
SA (1) SA110310698B1 (enExample)
SG (1) SG178451A1 (enExample)
TW (1) TW201119650A (enExample)
WO (1) WO2011030068A1 (enExample)
ZA (1) ZA201201400B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105272975B (zh) * 2014-06-10 2019-03-26 中国科学院上海药物研究所 一类具有1,2,4-恶二唑片段结构的吲哚生物碱及其制备方法和用途
WO2018136575A1 (en) * 2017-01-18 2018-07-26 Albert Einstein College Of Medicine, Inc. Pxr agonists and uses thereof for gut barrier dysfunction treatment and prevention

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1086950A1 (en) * 1998-05-26 2001-03-28 Chugai Seiyaku Kabushiki Kaisha Heterocyclic indole derivatives and mono- or diazaindole derivatives
WO2001082909A2 (de) * 2000-04-28 2001-11-08 Baxter Healthcare Sa 2-acyl-indolderivate und deren verwendung als antitumormittel
CN101304992A (zh) * 2005-09-07 2008-11-12 普莱希科公司 用作ppar调节剂的1,3-二取代吲哚衍生物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615441D0 (en) * 1996-07-23 1996-09-04 Pharmacia Spa Benzoylpropionic acid ester derivatives
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0119911D0 (en) 2001-08-15 2001-10-10 Novartis Ag Organic Compounds
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2004108094A2 (en) * 2003-06-06 2004-12-16 Atherogenics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
WO2005047268A2 (en) 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
WO2005056522A2 (en) 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
DK1761519T3 (da) * 2004-06-21 2008-07-21 Hoffmann La Roche Indolderivater som histaminreceptorantagonister
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
FR2903107B1 (fr) 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903106B1 (fr) 2006-07-03 2010-07-30 Sanofi Aventis Utilisations de 2-benzoyl-imidazopyridines en therapeutique
FR2903105A1 (fr) 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1086950A1 (en) * 1998-05-26 2001-03-28 Chugai Seiyaku Kabushiki Kaisha Heterocyclic indole derivatives and mono- or diazaindole derivatives
WO2001082909A2 (de) * 2000-04-28 2001-11-08 Baxter Healthcare Sa 2-acyl-indolderivate und deren verwendung als antitumormittel
CN101304992A (zh) * 2005-09-07 2008-11-12 普莱希科公司 用作ppar调节剂的1,3-二取代吲哚衍生物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GORDON W. GRIBBLE，等: "A Versatile and Efficient Construction of the 6H-Pyrido[4,3-b ]carbazole Ring System. Syntheses of the Antitumor Alkaloids Ellipticine9-Met hoxyellipticine, and Olivacine and Their Analogues", 《J. ORG. CHEM》, vol. 57, no. 22, 23 October 1992 (1992-10-23), pages 5891 - 5899 *
GORDON W. GRIBBLE，等: "Metalated Heterocycles in the Synthesis of Ellipticine Analogues. A NewRoute to the lOH-Pyrido[2,3-b]carbazole Ring System", 《J. ORG. CHEM》, vol. 54, no. 14, 1 January 1989 (1989-01-01), pages 3264 - 3269 *
JOHN C. RUCKDESCHELJP，等: "N-Methylcarbamate Derivatives of Ellipticine and Olivacine with CytotoxicActivity against Four Human Lung Cancer Cell Lines", 《J. MED. CHEM》, vol. 35, no. 26, 1 January 1992 (1992-01-01), pages 4854 - 4857 *

Also Published As

Publication number Publication date
IL218526A0 (en) 2012-07-31
MX2012003027A (es) 2012-04-19
US20120232070A1 (en) 2012-09-13
IN2012DN02005A (enExample) 2015-07-24
FR2950053B1 (fr) 2014-08-01
NZ598576A (en) 2014-05-30
TW201119650A (en) 2011-06-16
CL2012000632A1 (es) 2012-10-19
AR078358A1 (es) 2011-11-02
SG178451A1 (en) 2012-03-29
DOP2012000061A (es) 2012-09-30
EP2475642A1 (fr) 2012-07-18
AU2010294018A1 (en) 2012-03-29
SA110310698B1 (ar) 2014-11-16
CN103554006A (zh) 2014-02-05
CA2772697A1 (fr) 2011-03-17
CO6511224A2 (es) 2012-08-31
ECSP12011718A (es) 2012-04-30
FR2950058B1 (fr) 2016-04-01
FR2950053A1 (fr) 2011-03-18
WO2011030068A1 (fr) 2011-03-17
JP2013504548A (ja) 2013-02-07
PE20121346A1 (es) 2012-10-15
PH12012500390A1 (en) 2012-10-22
ZA201201400B (en) 2013-05-29
RU2012110883A (ru) 2013-10-20
KR20120065345A (ko) 2012-06-20
BR112012005480A2 (pt) 2019-09-24
CR20120131A (es) 2012-07-27
FR2950058A1 (fr) 2011-03-18

Similar Documents

Publication Publication Date Title
JP5301286B2 (ja) Ｆｘ受容体を調節するための化合物及び方法
AU2008276236B2 (en) Compounds and methods for modulating FXR
EP1513812B1 (en) Substituted indoles
AU781266B2 (en) Di-aryl acid derivatives as PPAR receptor ligands
US20030087902A1 (en) Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents
CN113939288A (zh) Mas相关g蛋白受体x4的调节剂及相关产物和方法
CN111936503A (zh) 噁嗪单酰甘油脂肪酶(magl)抑制剂
EA011010B1 (ru) Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
JP2010532363A (ja) ファルネソイドｘ受容体アゴニスト
CN102803235A (zh) 选择性调节cb2受体的化合物
TWI583687B (zh) ２－氧雜－５－氮雜雙環［２．２．１］庚－３－基衍生物
WO2022135442A1 (zh) Cdk2抑制剂及其制备方法
CN117794898A (zh) 3-吡咯基磺酰胺化合物作为gpr17拮抗剂
TW202328116A (zh) 含芳環類生物拮抗劑、其製備方法及應用
JP2008308496A (ja) 医薬
CN101563322A (zh) 用作ppar调节剂的1h-吲哚-2-甲酸衍生物
CN102596906A (zh) 吲哚衍生物作为nurr-1激活剂用作治疗帕金森病的药剂的用途
HK1191005A (en) Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease
CN116903559A (zh) Fxr调节剂及其应用
EP2521727B1 (fr) Nouveaux dérivés pyrrolopyridine benzoïques et leur utilisation pour le traitement de la maladie de parkinson
CN1980906A (zh) 作为ppar调节剂的化合物和组合物
CN118974013A (zh) 吡咯烷化合物
HK1178893B (en) New benzoic pyrrolopyridine derivatives and their use for the treatment of parkinson's disease
HK1109621A (en) Di-aryl acid derivatives as ppar receptor ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: YIWENDIWA CORP.

Free format text: FORMER OWNER: LABORATOIRES FOURNIER SA

Effective date: 20130930

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130930

Address after: Dijon

Applicant after: FOURNIER LAB SA

Address before: Dijon

Applicant before: Laboratoires Fournier S.A.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120718